The Joint Corp. (JYNT)

Healthcare · NCM

USD8.47+1.44% today

Fundamentals

Market capUSD125.59M
P/E ratio97.9
Revenue growth (YoY)+13.3%
Profit margin5.7%
Return on equity7.0%
52-week rangeUSD7.50 to USD11.75

Valuation and ratings

DCF fair valueUSD3.52
Upside to fair value-58.4%
Analyst target (mean)USD10.00
Analyst rangeUSD9.00 to USD12.00
Analysts covering3
Consensus viewnone
Moat score52/100
Overall rating31/100, Reduce

Fair value: USD3.52 (-58.4%), see how we got there

The Joint Corp. trades at USD8.47, which is 58% above the USD3.52 our discounted cash flow model puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.

Our moat model scores it 52 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.

It changes hands at 97.9 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.

JYNT earnings and analyst estimates

Next earnings date6 Aug 2026 (in 9 days)
EPS estimate, next yearUSD0.43
Expected EPS growth+56.6%
Expected revenue growth+3.0%

Recommendation mix, 4 analyst ratings

1 buy3 hold0 sell

Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.

About The Joint Corp.

The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. It operates through a network of franchised clinics, offering routine and affordable chiropractic adjustments using a private pay, non-insurance, cash-based model. The company was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Industry: Medical Care FacilitiesEmployees: 202HQ: United States

JYNT passes 1 of our 30 screens today

Each screen prints the exact criteria it used, and the circumstances in which it is wrong.

Common questions

Is The Joint Corp. (JYNT) undervalued?

Against our discounted cash flow estimate of USD3.52, JYNT at USD8.47 is 58% above fair value. That is one model's answer, not a recommendation, and most of a DCF's output sits in a terminal value nobody can forecast.

What is JYNT's P/E ratio?

JYNT trades at 97.9 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.

When does JYNT report earnings next?

The Joint Corp. is scheduled to report on 6 Aug 2026. Companies move earnings dates, so read it as scheduled rather than certain.

The full research page for JYNT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.